BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases... Show more
a developer of small molecule pharmaceuticals
Industry PharmaceuticalsGeneric
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FTKI | 19.27 | 0.11 | +0.58% |
| First Trust Small Cap Buywrite Income ETF | |||
| DIEM | 42.86 | 0.11 | +0.26% |
| Franklin Emerging Market Core Dividend Tilt Index ETF (DIEM) | |||
| TXBC | 18.63 | N/A | N/A |
| 21Shares FTSE Crypto 10 ex-BTC Index ETF (TXBC) | |||
| HPF | 13.46 | -0.01 | -0.07% |
| John Hancock Preferred Income Fund II | |||
| PIEQ | 35.78 | -0.23 | -0.63% |
| Principal International Equity ETF | |||
A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To BCRX | 1D Price Change % | ||
|---|---|---|---|---|
| BCRX | 100% | -2.52% | ||
| VCYT - BCRX | 46% Loosely correlated | -4.02% | ||
| HOWL - BCRX | 39% Loosely correlated | -4.42% | ||
| ROIV - BCRX | 38% Loosely correlated | -2.93% | ||
| BEAM - BCRX | 38% Loosely correlated | -0.25% | ||
| CLDX - BCRX | 37% Loosely correlated | -0.71% | ||
More | ||||
| Ticker / NAME | Correlation To BCRX | 1D Price Change % |
|---|---|---|
| BCRX | 100% | -2.52% |
| Pharmaceuticals category (154 stocks) | 15% Poorly correlated | -0.74% |
| Pharmaceuticals: Generic category (83 stocks) | 14% Poorly correlated | -0.92% |
The RSI Indicator for BCRX moved out of oversold territory on September 16, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 36 similar instances when the indicator left oversold territory. In 31 of the 36 cases the stock moved higher. This puts the odds of a move higher at 86%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +1.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCRX advanced for three days, in 204 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
BCRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BCRX as a result. In 82 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for BCRX turned negative on September 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 45 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
BCRX moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BCRX crossed bearishly below the 50-day moving average on September 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for BCRX entered a downward trend on September 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-25.695) is normal, around the industry mean (43.873). P/E Ratio (7.463) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.097) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. BCRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.